The clinical application of intradermal acupuncture in treating rheumatoid arthritis

注册号:

Registration number:

ITMCTR2000003913

最近更新日期:

Date of Last Refreshed on:

2020-09-08

注册时间:

Date of Registration:

2020-09-08

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

揿针治疗类风湿关节炎的临床应用研究

Public title:

The clinical application of intradermal acupuncture in treating rheumatoid arthritis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

揿针治疗类风湿关节炎的临床应用研究

Scientific title:

The clinical application of intradermal acupuncture in treating rheumatoid arthritis

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2000038028 ; ChiMCTR2000003913

申请注册联系人:

罗辉芳

研究负责人:

杨湘薇

Applicant:

Luo Huifang

Study leader:

Yang Xiangwei

申请注册联系人电话:

Applicant telephone:

+86 13723580784

研究负责人电话:

Study leader's telephone:

13570919326

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2334108613@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1327758056@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

广州中医药大学三元里校区

研究负责人通讯地址:

广州市机场路12号

Applicant address:

Guangzhou University of Chinese Medicine Sanyuanli Campus

Study leader's address:

12 Airport Road, Baiyun District, Guangzhou, Guangdong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广州中医药大学护理学院

Applicant's institution:

School of Nursing, Guangzhou University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

NO.ZYYECK[2020]075

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

广州中医药大学第一附属医院伦理委员会

Name of the ethic committee:

Ethics Committee of the First Affiliated Hospital of Guangzhou University of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2020/8/31 0:00:00

伦理委员会联系人:

黎欣盈

Contact Name of the ethic committee:

Xin-Ying Li

伦理委员会联系地址:

广州市机场路12号

Contact Address of the ethic committee:

12 Airport Road, Baiyun District, Guangzhou, Guangdong

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广州中医药大学第一附属医院风湿科

Primary sponsor:

Department of Rheumatology, the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

广州市机场路12号

Primary sponsor's address:

12 Airport Road, Baiyun District, Guangzhou, Guangdong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广州中医药大学第一附属医院

具体地址:

机场路12号

Institution
hospital:

The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine

Address:

12 Airport Road

经费或物资来源:

创新强院工程(二期)

Source(s) of funding:

Innovation and Strong Institute Project (Phase II)

研究疾病:

类风湿性关节炎

研究疾病代码:

Target disease:

Rheumatoid arthritis

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

本研究拟将揿针用于类风湿关节炎患者的治疗,观察其临床疗效、不良反应及安全性等,形成规范治疗方案,进行临床推广应用,促进疾病康复,提高患者生活质量。

Objectives of Study:

This study intends to apply the intradermal acupuncture to the treatment of patients with rheumatoid arthritis, observe its clinical efficacy, adverse reactions and safety, etc., form a standardized treatment plan, carry out clinical promotion and application, promote disease recovery, and improve the quality of life of patients.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

⑴ 西医诊断第一诊断为类风湿关节炎,中医诊断第一诊断为尪痹。 ⑵ 西医诊断标准参照1987年美国风湿病学会(ARA)修订的类风湿关节炎分类标准和2009年ACR/EULAR类风湿关节炎分类标准。中医诊断标准参照中华人民共和国中医药行业标准《中医病证诊断疗效标准》(ZY/T001.1-94) ⑶ 证候诊断参照“国家中医药管理局‘十一五’重点专科协作组尪痹(类风湿关节炎)诊疗方案”,选取肝肾不足证型的患者。 ⑷ DAS28评分属于轻度活动或不活动的患者,依然有四肢关节痛。 ⑸ 年龄在18周岁以上,并自愿参与本研究。

Inclusion criteria

⑴ The first diagnosis of Western medicine was rheumatoid arthritis, and the first diagnosis of TCM was Wangbi. ⑵ The diagnostic criteria of western medicine refer to the classification standard of rheumatoid arthritis revised by the American Academy of Rheumatology (ARA) in 1987 and the classification standard of ACR/EULAR rheumatoid arthritis in 2009. The diagnostic criteria of traditional Chinese medicine refer to the standard of the Chinese medicine industry of the Peoples Republic of China, "Standards for Diagnosis and Efficacy of TCM Diseases and Syndromes" (ZY/T001.1-94). ⑶ Syndrome diagnosis refers to the "Eleventh Five-Year" Key Specialty Collaborative Group of the State Administration of Traditional Chinese Medicine, and selects patients with liver and kidney deficiency syndromes. ⑷ DAS28 score belongs to patients with mild activity or inactivity, and still have limb joint pain. ⑸ Aged over 18 years and volunteer to participate in this research.

排除标准:

⑴ 合并严重的心肺疾病、肝肾疾病、糖尿病、冠心病等。 ⑵ 合并血液系统疾病及恶性肿瘤。 ⑶ 妊娠或哺乳期妇女。 ⑷ 发热或凝血功能障碍。 ⑸ 治疗局部皮肤有破溃或皮肤病者。

Exclusion criteria:

⑴ Combined with serious cardiopulmonary disease, liver and kidney disease, diabetes, coronary heart disease, etc. ⑵ Combined with hematological diseases and malignant tumors. ⑶ Pregnant or lactating women. ⑷ Fever or coagulopathy. ⑸ Treatment of local skin ulcers or skin diseases.

研究实施时间:

Study execute time:

From 2020-07-06

To      2022-07-05

征募观察对象时间:

Recruiting time:

From 2020-09-25

To      2021-07-31

干预措施:

Interventions:

组别:

试验组

样本量:

50

Group:

Trial group

Sample size:

干预措施:

实施类风湿关节炎的基础治疗及护理常规+揿针组

干预措施代码:

Intervention:

Implement basic treatment and nursing routine of rheumatoid arthritis + intradermal acupuncture group

Intervention code:

组别:

对照组

样本量:

50

Group:

Control group

Sample size:

干预措施:

实施类风湿关节炎的基础治疗及护理常规+假揿针组

干预措施代码:

Intervention:

Implement basic treatment and nursing routine of rheumatoid arthritis + fake intradermal acupuncture group

Intervention code:

样本总量 Total sample size : 100

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广州中医药大学第一附属医院

单位级别:

三甲

Institution/hospital:

The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

不良反应

指标类型:

次要指标

Outcome:

Adverse reactions

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

类风湿关节炎患者健康评估问卷(HAQ)评分

指标类型:

主要指标

Outcome:

Rheumatoid Arthritis Patient Health Assessment Questionnaire (HAQ) score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清CRP

指标类型:

次要指标

Outcome:

Serum CRP

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

DAS28评分

指标类型:

主要指标

Outcome:

DAS28 score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者中医证候学评价

指标类型:

主要指标

Outcome:

Evaluation of TCM Syndrome of Patients

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它

说明

Fate of sample 

Others

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机分配操作由广州中医药大学第一附属医院数据管理专员完成。使用计算机软件生成随机数,采用随机数字表的方法进行分组,将随机数字(1代表对照组,2代表干预组)制作成数字卡片,放进连续编码的信封中,符合纳入标准的患者,按照纳入研究的次序,依照信封上的编码拆开取出封内的数字卡,严格按卡片序号规定分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

The random assignment operation is completed by the data management specialist of the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine. Use computer software to generate random numbers, use random number table method for grouping, make random numbers (1 for the control group, 2 for&

盲法:

对受试者设盲

Blinding:

Blind method for subjects.

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成6个月后,如有合理需求,请联系研究负责人获取研究原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Contact principal investigator to acquire IPD six months after the trial complete, as long as the acquire is reasonable

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集用量表和客观指标,数据管理使用SPSS软件

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection meter and objective indicators, SPSS software for data management

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above